Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012-Reference-Cited by-同舟云学术

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012

Published:2014-06-25 Issue:3 Volume:167 Page:418-420
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Reilly John T.¹,McMullin Mary Frances²,Beer Philip A.³,Butt Nauman⁴,Conneally Eibhlin⁵,Duncombe Andrew S.⁶,Green Anthony R.⁷,Mikhaeel George⁸,Gilleece Marie H.⁹,Knapper Steven¹⁰,Mead Adam J.¹¹,Mesa Ruben A.¹²,Sekhar Mallika¹³,Harrison Claire N.⁸

Affiliation:

1. Sheffield Teaching Hospitals NHS Trust; Sheffield UK

2. Queen's University; Belfast UK

3. Terry Fox Laboratory; BC Cancer Agency; Vancouver BC Canada

4. The Royal Liverpool and Broadgreen University Hospitals NHS Trust; Liverpool UK

5. St. James's Hospital; Dublin Ireland

6. Department of Haematology; University Hospital Southampton; Southampton UK

7. University of Cambridge; Cambridge UK

8. Guy's and St Thomas' NHS Foundation Trust; London UK

9. St James Univeristy Hospital; Leeds UK

10. Cardiff University; Cardiff UK

11. University of Oxford; Oxford UK

12. Mayo Clinic; Scottsdale AZ USA

13. Royal Free Hospital NHS Trust; London UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12985/fullpdf

Reference10 articles.

1. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis;Cervantes;Blood,2013

2. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs;Emanuel;Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2012

3. Practical management of patients with myelofibrosis receiving ruxolitinib;Harrison;Expert Review of Hematology,2013

4. Somatic mutations of calreticulin in myeloproliferative neoplasms;Klampfl;New England Journal of Medicine,2013

5. Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study;McMullin;Blood (ASH Annual Meeting Abstracts),2011

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The management of myelofibrosis: A British Society for Haematology Guideline;British Journal of Haematology;2023-12

2. Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline;British Journal of Haematology;2023-11-06

3. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group;Clinical and Experimental Medicine;2023-09-25

4. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis;Blood Advances;2022-03-17

5. Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice;Blood Reviews;2020-07